Dr. Ananth K. Arjunan, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Texas Tech University Health Science Center School of Medicine (2011)
- Years since graduation
- 15
- In the NPI registry since
- 2011
- Medicare patients seen, 2024
- 396
Licensed in Texas since 2018, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2011Medical school: Texas Tech University Health Science Center School of Medicine
- 2011Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
TX license R8150 (first issued 2018; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Baylor Scott & White Medical Center- Waxahachie Waxahachie, TX
- Methodist Dallas Medical Center Dallas, TX
- Methodist Charlton Medical Center Dallas, TX
- Methodist Midlothian Medical Center Midlothian, TX
Medical groups
- Texas Oncology PA (1,014 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 396
- Services billed
- 118,483
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Injection, iron sucrose, 1 mg | 20,200 | 37 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 11,755 | 15 |
| Injection, pembrolizumab, 1 mg | 8,200 | 13 |
| Injection, fosaprepitant, 1 mg | 5,250 | 12 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 2,400 | 19 |
| Injection, dexamethasone sodium phosphate, 1 mg | 930 | 37 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 595 | 202 |
| Insertion of needle into vein for collection of blood sample | 564 | 191 |
| Injection, palonosetron hcl, 25 mcg | 470 | 17 |
| Injection, granisetron hydrochloride, 100 mcg | 440 | 19 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Anastrozole Other prescribers in Dallas, TX | 116 |
| Eliquis (apixaban) Other prescribers in Dallas, TX | 91 |
| Ondansetron Odt (ondansetron) Other prescribers in Dallas, TX | 64 |
| Revlimid (lenalidomide) | 58 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Dallas, TX | 50 |
| Dexamethasone Other prescribers in Dallas, TX | 50 |
| Hydroxyurea Other prescribers in Dallas, TX | 46 |
| Xarelto (rivaroxaban) Other prescribers in Dallas, TX | 44 |
| Gabapentin Other prescribers in Dallas, TX | 41 |
| Brukinsa (zanubrutinib) | 39 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 50 companies reported 179 payments worth $13,841 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $8,554 |
|---|---|
| Pfizer Inc. | $1,664 |
| Karyopharm Therapeutics Inc. | $268 |
| Janssen Biotech, Inc. | $237 |
| Gilead Sciences, Inc. | $191 |
| AbbVie Inc. | $176 |
| E.r. Squibb & Sons, L.l.c. | $158 |
| Regeneron Healthcare Solutions, Inc. | $154 |
| Compensation for services other than consulting (speaking, faculty) | $7,870 |
|---|---|
| Food and Beverage | $4,316 |
| Consulting Fee | $1,300 |
| Honoraria | $191 |
| Travel and Lodging | $86.94 |
| Education | $77.99 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP Jul 28, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionSpeaker Fee | $4,020 |
| AstraZeneca Pharmaceuticals LP Jul 1, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionSpeaker Fee | $3,350 |
| Pfizer Inc. May 14, 2025 | Consulting Fee IBRANCE · ONCOLOGY | $1,300 |
| AstraZeneca Pharmaceuticals LP Apr 2, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionSpeaker Fee | $250 |
| AstraZeneca Pharmaceuticals LP Sep 26, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionSpeaker Fee | $250 |
| Karyopharm Therapeutics Inc. Apr 3, 2025 | Honoraria XPOVIO · Oncology | $191 |
| Daiichi Sankyo Inc. Jun 6, 2025 | Education Enhertu · ONCOLOGY · in-kind | $77.99 |
| AstraZeneca Pharmaceuticals LP Jul 28, 2025 | Travel and Lodging travel to McKinney, TX | $53.90 |
| AstraZeneca Pharmaceuticals LP Jul 1, 2025 | Travel and Lodging travel to Dallas, TX | $33.04 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.